Evidence map›Paper›PMID 21537012›Full record

ArticleAntimicrobial agents and chemotherapy2011

Adaptation and antibiotic tolerance of anaerobic Burkholderia pseudomallei.

Mohamad A Hamad, Chad R Austin, Amanda L Stewart, Mike Higgins, Andrés Vázquez-Torres, Martin I Voskuil

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 81 citations in OpenAlex.

  1. Review
  2. Review
  3. Proteomic comparison of epidemic AustralianMicrobiology spectrum · 2025
    Article
  4. Article
  5. Hijacking anaerobic metabolism to restore antibiotic efficacy inApplied and environmental microbiology · 2025
    Article
  6. Targeting Anaerobic Respiration inAdvances in wound care · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Metabolic pathways that permitFrontiers in cellular and infection microbiology · 2023
    Article
  11. Article
  12. Tolerance to Ceftriaxone inAntibiotics (Basel, Switzerland) · 2022
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mohamad A HamadDepartment of Microbiology, University of Colorado School of Medicine, Aurora, Colorado 80045, USA.
Chad R Austin
Amanda L Stewart
Mike Higgins
Andrés Vázquez-Torres
Martin I Voskuil
University of Colorado Denver · US

Funding

Vascular stabilization as a broad theraprutic platform for biodefenseU54AI065357 · NIAID · COLORADO STATE UNIVERSITY-FORT COLLINS · PI SCHWEIZER, HERBERT P. · 2005 to 2013
$77.5M
NIAID NIH HHS U54 AI-065357NIAID NIH HHS U54 AI065357
6 · The paper itself

Abstract

The Gram-negative bacterium Burkholderia pseudomallei is the etiological agent of melioidosis and is remarkably resistant to most classes of antibacterials. Even after months of treatment with antibacterials that are relatively effective in vitro, there is a high rate of treatment failure, indicating that this pathogen alters its patterns of antibacterial susceptibility in response to cues encountered in the host. The pathology of melioidosis indicates that B. pseudomallei encounters host microenvironments that limit aerobic respiration, including the lack of oxygen found in abscesses and in the presence of nitric oxide produced by macrophages. We investigated whether B. pseudomallei could survive in a nonreplicating, oxygen-deprived state and determined if this physiological state was tolerant of conventional antibacterials. B. pseudomallei survived initial anaerobiosis, especially under moderately acidic conditions similar to those found in abscesses. Microarray expression profiling indicated a major shift in the physiological state of hypoxic B. pseudomallei, including induction of a variety of typical anaerobic-environment-responsive genes and genes that appear specific to anaerobic B. pseudomallei. Interestingly, anaerobic B. pseudomallei was unaffected by antibacterials typically used in therapy. However, it was exquisitely sensitive to drugs used against anaerobic pathogens. After several weeks of anaerobic culture, a significant loss of viability was observed. However, a stable subpopulation that maintained complete viability for at least 1 year was established. Thus, during the course of human infection, if a minor subpopulation of bacteria inhabited an oxygen-restricted environment, it might be indifferent to traditional therapy but susceptible to antibiotics frequently used to treat anaerobic infections.

Indexed as

Anti-Bacterial AgentsBacteria, AnaerobicBurkholderia pseudomalleiCeftazidimeHydrogen-Ion ConcentrationNitroimidazolesTrimethoprim, Sulfamethoxazole Drug CombinationAnti-Bacterial AgentsCeftazidimeNitroimidazolesTrimethoprim, Sulfamethoxazole Drug Combination

Identifiers

PMID21537012
PMCPMC3122399
OpenAlexW2159696489

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.